Hollande and colleagues emphasised the role of CCL11 by demonstrating that dipeptidyl peptidase DPP4 (CD26) inhibitor sitagliptin led to enhanced tumor control through enhanced CCL11-mediated eosinophil recruitment at the tumor site [51]. The gene discussed is CCL11; the disease is neoplasm.